Viewing Study NCT03091192

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:37 PM
Ignite Modification Date: 2026-05-03 @ 9:37 PM
Study NCT ID: NCT03091192
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-09-15
First Post: 2017-02-09
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Savolitinib vs. Sunitinib in MET-driven PRCC.
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma View
None Carcinoma, Renal Cell View
None Kidney Neoplasms View
None Urologic Neoplasms View
None Kidney Diseases View
None Neoplasms by Site View
None Enzyme Inhibitors View
None Protein Kinase Inhibitors View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Papillary Renal Cell Cancer View
None AZD6094 View
None Savolitinib View